Mehta-Shah, N., Jacobsen, E., Luigi Zinzani, P., Zain, J., Mead, M., Casulo, C., Gritti, G., Pinter-Brown, L., Izutsu, K., Waters, S., Brammer, J., Pro, B., & Horwitz, S. (2023). P1124: DUVELISIB IN PATIENTS WITH RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA FROM THE PHASE 2 PRIMO TRIAL EXPANSION PHASE: OUTCOMES BY BASELINE HISTOLOGY. HemaSphere, 7(S3), e3891642. https://doi.org/10.1097/01.hs9.0000971392.38916.42

Kim, W.-S., Shortt, J., Luigi Zinzani, P., Mikhaylova, N., Marin-Niebla, A., Radeski, D., Ribrag, V., Domingo Domènech, E., Sawas, A., Alexis, K., Emig, M., Garcia, L., Overesch, A., Pietzko, K., & Horwitz, S. (2023). P1142: AFM13 IN PATIENTS WITH R/R PERIPHERAL T CELL LYMPHOMA (PTCL): A POST-HOC SUBGROUP ANALYSIS FROM THE REDIRECT STUDY. HemaSphere, 7(S3), e6843062. https://doi.org/10.1097/01.hs9.0000971464.68430.62

Flinn, I. W., Jacobson, C., Nastoupil, L. J., Morschhauser, F., Davies, A. J., Buske, C., Corradini, P., Lopez-Guillermo, A., Reshef, R., Parameswaran, V., Sehgal, A., Tees, M., Lui, C., Xue, W., Beygi, S., Grechko, N., Bolsue, P., Giovanetti, A., To, C., & Nahas, M. (2023). P1107: ZUMA-22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD-OF-CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. HemaSphere, 7(S3), e6350662. https://doi.org/10.1097/01.hs9.0000971324.63506.62

Senna, M., Forman, S., Bordone, L., De La Cueva Dobao, P., Wolk, R., Zwillich, S., Zhang, F., Mohamed Ahmed, H., & Takiya, L. (2023). Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study. SKIN The Journal of Cutaneous Medicine, 7(4), s224. https://doi.org/10.25251/skin.7.supp.224

Di Meo, F., Iyer, A., Akama, K., Cheng, R., Yu, C., Cesarano, A., Kurihara, N., Tenshin, H., Aljoufi, A., Marino, S., Soni, R. K., Roda, J., Sissons, J., Vu, L. P., Guzman, M., Huang, K., Laskowski, T., Broxmeyer, H. E., Roodman, D. G., & Perna, F. (2023). A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma. Cell Reports Medicine, 4(7), 101110. https://doi.org/10.1016/j.xcrm.2023.101110

Amengual, J. E., Reagan, P., Li, H., Saeed, H., Vaidya, R., Unger, J. M., Danilov, A., LeBlanc, M., Friedberg, J. W., & Smith, S. M. (2023). S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL. Hematological Oncology, 41(S2), 842–843. Portico. https://doi.org/10.1002/hon.3166_ot22

Flinn, I. W., Jacobson, C. A., Nastoupil, L. J., Morschhauser, F., Davies, A., Buske, C., Corradini, P., Lopez‐Guillermo, A., Reshef, R., Parameswaran, V., Sehgal, A., Tees, M., Lui, C., Xue, W., Beygi, S., Grechko, N., Bolsue, P., Giovanetti, A., To, C., & Nahas, M. (2023). ZUMA‐22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) VS STANDARD‐OF‐CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA. Hematological Oncology, 41(S2), 853–855. Portico. https://doi.org/10.1002/hon.3166_ot31

Hess, B., Li, H., Hossain, N., Beylergil, V., Sauter, C., Hamadani, M., Svoboda, J., Major, A., Kahl, B., Leonard, J. P., Smith, S., LeBlanc, M., Stiff, P., & Friedberg, J. W. (2023). SWOG 2114: A RANDOMIZED PHASE II TRIAL OF CONSOLIDATION THERAPY FOLLOWING CD19 CAR T‐CELL TREATMENT FOR RELAPSED/REFRACTORY LARGE B‐CELL OR GRADE IIIB FOLLICULAR LYMPHOMA. Hematological Oncology, 41(S2), 839–840. Portico. https://doi.org/10.1002/hon.3166_ot19

Mehta‐Shah, N., Jacobsen, E. D., Zinzani, P. L., Zain, J., Mead, M., Casulo, C., Gritti, G., Pinter‐Brown, L., Izutsu, K., Waters, S., Brammer, J. E., Pro, B., & Horwitz, S. M. (2023). Duvelisib in patients with relapsed/refractory peripheral T‐cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology. Hematological Oncology, 41(S2), 499–500. Portico. https://doi.org/10.1002/hon.3164_367

Kim, W. S., Shortt, J., Zinzani, P. L., Mikhaylova, N., Marin‐Niebla, A., Radeski, D., Ribrag, V., Domenech, E. D., Sawas, A., Alexis, K., Emig, M., Garcia, L., Overesch, A., Pietzko, K., & Horwitz, S. (2023). AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY (R/R) PERIPHERAL T CELL LYMPHOMA (PTCL): RESULTS FROM THE PHASE 2 REDIRECT STUDY. Hematological Oncology, 41(S2), 195–196. Portico. https://doi.org/10.1002/hon.3163_126

Youssef, S., Lavian, J., Lee, E. Y., Fan, W., & Bordone, L. A. (2023). Tofacitinib therapy for alopecia areata is not associated with adverse events during COVID-19 infection. Journal of the American Academy of Dermatology, 88(5), 1125–1127. https://doi.org/10.1016/j.jaad.2022.05.005

Cherng, H.-J. J., Alig, S. K., Oki, Y., Nastoupil, L. J., Fayad, L., Neelapu, S. S., Turturro, F., Hagemeister, F., Craig, A. F. M., Macaulay, C. W., Rodriguez, M. A., Lee, H. J., McDonnell, T. J., Flowers, C. R., Vega, F., Green, M. R., Feng, L., Kurtz, D. M., Alizadeh, A. A., … Westin, J. R. (2023). A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Advances, 7(7), 1137–1145. https://doi.org/10.1182/bloodadvances.2022008174

Geskin, L. J., Kwinta, B. D., Garcia-Saleem, T. J., Akilov, O. E., Enz, P. A., Guenova, E., Ortiz-Romero, P. L., Papadavid, E., Quaglino, P., Rozati, S., Stonesifer, C. J., Burns, A., Stringer, W. S., Tarin, E., & Scarisbrick, J. J. (2023). International Society for Cutaneous Lymphomas Pandemic Section (ICLYPS) analysis of cutaneous T-cell lymphoma outcomes during the COVID-19 pandemic: A retrospective cohort study. Journal of the American Academy of Dermatology, 88(4), 935–937. https://doi.org/10.1016/j.jaad.2022.11.016

Rancan, C., Arias-Badia, M., Dogra, P., Chen, B., Aran, D., Yang, H., Luong, D., Ilano, A., Li, J., Chang, H., Kwek, S. S., Zhang, L., Lanier, L. L., Meng, M. V., Farber, D. L., & Fong, L. (2023). Exhausted intratumoral Vδ2− γδ T cells in human kidney cancer retain effector function. Nature Immunology, 24(4), 612–624. https://doi.org/10.1038/s41590-023-01448-7

Hamid, O., Lewis, K., Weise, A., McKean, M., Papadopoulos, K. P., Crown, J., Kim, T. M., Lakhani, N. J., Kaczmar, J., Kudchadkar, R., Spira, A., Rabinowits, G., Kim, K., Carvajal, R., Williamson, S., Ioffe, E., Chen, S., Mani, J., Jankovic, V., … Gullo, G. (2023). Phase 1 study of fianlimab, a human lymphocyte activation gene-3 monoclonal antibody, in combination with cemiplimab in advanced melanoma: Expansion cohort analysis. SKIN The Journal of Cutaneous Medicine, 7(2), s179. https://doi.org/10.25251/skin.7.supp.179

Savage, T. M., Vincent, R. L., Rae, S. S., Huang, L. H., Ahn, A., Pu, K., Li, F., de los Santos-Alexis, K., Coker, C., Danino, T., & Arpaia, N. (2023). Chemokines expressed by engineered bacteria recruit and orchestrate antitumor immunity. Science Advances, 9(10). https://doi.org/10.1126/sciadv.adc9436

Wayne, A. S., Huynh, V., Hijiya, N., Rouce, R. H., Brown, P. A., Krueger, J., Kitko, C. L., Ziga, E. D., Hermiston, M. L., Richards, M. K., Baruchel, A., Schuberth, P. C., Rossi, J., Zhou, L., Goyal, L., Jain, R., Vezan, R., Masouleh, B. K., & Lee, D. W. (2022). Three-year results from phase I of ZUMA-4: KTE-X19 in pediatric relapsed/refractory acute lymphoblastic leukemia. Haematologica, 108(3), 747–760. https://doi.org/10.3324/haematol.2022.280678

Kim, H. S., Ho, T.-C., Willner, M. J., Becker, M. W., Kim, H.-W., & Leong, K. W. (2023). Dendritic cell-mimicking scaffolds for ex vivo T cell expansion. Bioactive Materials, 21, 241–252. https://doi.org/10.1016/j.bioactmat.2022.08.015

Stefanski, H. E., Eaton, A., Baggott, C., Rossoff, J., Verneris, M. R., Prabhu, S., Pacenta, H. L., Phillips, C. L., Talano, J.-A., Moskop, A., Margossian, S. P., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M., Satwani, P., Krupski, M. C., Keating, A. K., … Schultz, L. M. (2023). Higher doses of tisagenlecleucel are associated with improved outcomes: a report from the pediatric real-world CAR consortium. Blood Advances, 7(4), 541–548. https://doi.org/10.1182/bloodadvances.2022007246

Gartshteyn, Y., Askanase, A. D., Song, R., Bukhari, S., Dragovich, M., Adam, K., & Mor, A. (2022). SLAMF6 compartmentalization enhances T cell functions. Life Science Alliance, 6(2), e202201533. https://doi.org/10.26508/lsa.202201533

Bukhari, S., Henick, B. S., Winchester, R. J., Lerrer, S., Adam, K., Gartshteyn, Y., Maniar, R., Lin, Z., Khodadadi-Jamayran, A., Tsirigos, A., Salvatore, M. M., Lagos, G. G., Reiner, S. L., Dallos, M. C., Mathew, M., Rizvi, N. A., & Mor, A. (2023). Single-cell RNA sequencing reveals distinct T cell populations in immune-related adverse events of checkpoint inhibitors. Cell Reports Medicine, 4(1), 100868. https://doi.org/10.1016/j.xcrm.2022.100868

Gartrell, R. D., Enzler, T., Kim, P. S., Fullerton, B. T., Fazlollahi, L., Chen, A. X., Minns, H. E., Perni, S., Weisberg, S. P., Rizk, E. M., Wang, S., Oh, E. J., Guo, X. V., Chiuzan, C., Manji, G. A., Bates, S. E., Chabot, J., Schrope, B., Kluger, M., … Saenger, Y. M. (2022). Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma. OncoImmunology, 11(1). https://doi.org/10.1080/2162402x.2022.2066767

Phares, T. W., Huang, J., Kotraiah, V., Hauser, M. J., Domi, A., Oruganti, S., Browne, C. D., Buontempo, P., Mansour, M., Pannucci, J., Tsuji, M., & Gutierrez, G. M. (2022). Viral delivery of a peptide-based immunomodulator enhances T cell priming during vaccination. Frontiers in Pharmacology, 13. https://doi.org/10.3389/fphar.2022.1029636

Anandakumaran, P. N., Ayers, A. G., Muranski, P., Creusot, R. J., & Sia, S. K. (2022). Rapid video-based deep learning of cognate versus non-cognate T cell-dendritic cell interactions. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-021-04286-5

Strazza, M., Moore, E. K., Adam, K., Azoulay-Alfaguter, I., & Mor, A. (2022). Neutralization of the adaptor protein PAG by monoclonal antibody limits murine tumor growth. Molecular Therapy - Methods & Clinical Development, 27, 380–390. https://doi.org/10.1016/j.omtm.2022.10.012

Thummar, K., & Rathinam, C. V. (2022). Class I PI3K regulatory subunits control differentiation of dendritic cell subsets and regulate Flt3L mediated signal transduction. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-16548-x

Prince, H. M. M., Geskin, L. J., Akilov, O. E., Kuzel, T. M., Querfeld, C., Ooi, C. E., Xing, D., Sauter, N., Singh, P., Czuczman, M., & Foss, F. M. (2022). Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302. Blood, 140(Supplement 1), 6577–6578. https://doi.org/10.1182/blood-2022-167564

Di Meo, F., Iyer, A., Akama, K., Yu, C., Cheng, R., Cesarano, A., Marino, S., Aljoufi, A., Soni, R., Roda, J. M., Sissons, J., Vu, L. P., Guzman, M. L., Huang, K., Roodman, D. G., & Perna, F. (2022). A Novel Bi-Specific T-Cell Engager Targeting ILT3 Is Potently Effective in Multiple Myeloma. Blood, 140(Supplement 1), 671–672. https://doi.org/10.1182/blood-2022-167584

Roy, I., Epperla, N., Shouse, G., Romancik, J. T., Moyo, T. K., Kenkre, V. P., Ollila, T. A., Fitzgerald, L. A., Hess, B. T., Evens, A. M., Zurko, J., Chowdhury, S. M., Annunzio, K., Ferdman, R., Bhansali, R. S., Harris, E. I., Sorrell, M., Liu, J., Nizamuddin, I. A., … Karmali, R. (2022). Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy. Blood, 140(Supplement 1), 2416–2418. https://doi.org/10.1182/blood-2022-163822

Fabrizio, V. A., Miller, K., Baggott, C., Prabhu, S., Pacenta, H., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J., Moskop, A., Baumeister, S. H. C., Myers, G. D., Karras, N., Brown, P. A., Qayed, M., Hermiston, M. L., Satwani, P., Krupski, C., Wilcox, R., … Schultz, L. M. (2022). Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults. Blood, 140(Supplement 1), 4661–4663. https://doi.org/10.1182/blood-2022-169603

Usmani, S., Patel, K., Hari, P., Berdeja, J., Alsina, M., Vij, R., Raje, N., Leleu, X., Dhodapkar, M., Reshef, R., Truppel-Hartmann, A., Basudhar, D., Thompson, E., Zheng, X., Ananthakrishnan, R., Greggio, C., Favre-Kontula, L., Sternas, L., & San-Miguel, J. (2022). KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation. Blood, 140(Supplement 1), 875–877. https://doi.org/10.1182/blood-2022-162469

Chakraborty, R., Behera, T. R., Li, H., Dean, R. M., Hill, B. T., Jagadeesh, D., Winter, A., Anwer, F., Pohlman, B., Sobecks, R. M., Hamilton, B. K., & Majhail, N. S. (2022). Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study. Blood, 140(Supplement 1), 10926–10927. https://doi.org/10.1182/blood-2022-166904

Jacobsen, E. D., Zinzani, P. L., Zain, J., Mead, M., Casulo, C., Gritti, G., Pinter-Brown, L. C., Izutsu, K., Daugherty, M., Brammer, J. E., Mehta-Shah, N., Pro, B., & Horwitz, S. M. (2022). Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis. Blood, 140(Supplement 1), 9387–9389. https://doi.org/10.1182/blood-2022-169432

Capellini, A., Etra, A., Alousi, A. M., Al Malki, M. M., Choe, H., Defilipp, Z., Hogan, W. J., Kitko, C. L., Ayuk, F. A., Baez, J., Gandhi, I., Kasikis, S., Gleich, S., Hexner, E. O., Hoepting, M., Kapoor, U., Kowalyk, S., Kwon, D., Langston, A., … Levine, J. E. (2022). Effective Treatment of Low Risk Acute Gvhd with Itacitinib Monotherapy. Blood, 140(Supplement 1), 1867–1869. https://doi.org/10.1182/blood-2022-156000

Molina, J. C., Chinnabhandar, V., Fabrizio, V. A., Kunicki, M., Pacenta, H., Rossoff, J., Stefanski, H. E., Talano, J., Moskop, A., Verneris, M. R., Myers, G. D., Karras, N., Baggott, C., Qayed, M., Hermiston, M. L., Satwani, P., Krupski, C., Keating, A. K., Baumeister, S. H. C., … Smith, S. M. (2022). Standard Cytogenetic Risk Stratification Is Not Predictive of CD19 CAR Outcomes and Impact of Disease Burden Varies between Cytogenetic Risk Groups. Blood, 140(Supplement 1), 10386–10388. https://doi.org/10.1182/blood-2022-165951

Baljevic, M., Gasparetto, C., Schiller, G. J., Tuchman, S. A., Callander, N. S., Lentzsch, S., Monge, J., Kotb, R., Bahlis, N. J., White, D., Chen, C. I., Sutherland, H. J., Madan, S., LeBlanc, R., Sebag, M., Venner, C. P., Bensinger, W. I., Biran, N., DeCastro, A., … Lipe, B. (2022). Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment. EJHaem, 3(4), 1270–1276. Portico. https://doi.org/10.1002/jha2.572

Bagley, S., Polley, M.-Y., Kotecha, R., Brem, S., Tolakanahalli, R., Iwamoto, F., Gilbert, M., Won, M., & Mehta, M. (2022). CTIM-21. NRG-BN010: A SAFETY RUN-IN AND PHASE II STUDY EVALUATING THE COMBINATION OF TOCILIZUMAB, ATEZOLIZUMAB, AND FRACTIONATED STEREOTACTIC RADIOTHERAPY IN RECURRENT GLIOBLASTOMA – TRIAL IN PROGRESS. Neuro-Oncology, 24(Supplement_7), vii64–vii64. https://doi.org/10.1093/neuonc/noac209.253

Koh, S. K., Park, J., Kim, S.-E., Lim, Y., Phan, M.-T. T., Kim, J., Hwang, I., Ahn, Y.-O., Shin, S., Doh, J., & Cho, D. (2022). Natural Killer Cell Expansion and Cytotoxicity Differ Depending on the Culture Medium Used. Annals of Laboratory Medicine, 42(6), 638–649. https://doi.org/10.3343/alm.2022.42.6.638

Friedman, C., Carvajal, R., Davar, D., Castanon, E., Ascierto, P., Calvo, E., O’Hara, M., Powell, S., Shapira-Frommer, R., Garralda, E., Renouf, D. J., Perets, R., Yunan, M., Ravindran, P., Hammell, A., O’Brien, S., Xu, K., Wilson, N., Jhatakia, A., … Gutierrez, M. (2022). 592 Phase 1/2a study of the novel nonfucosylated anti–CTLA-4 monoclonal antibody BMS-986218 ± nivolumab in advanced solid tumors: part 1 results. Regular and Young Investigator Award Abstracts, A620–A621. https://doi.org/10.1136/jitc-2022-sitc2022.0592

Hamid, O., Chiappori, A. A., Thompson, J. A., Doi, T., Hu-Lieskovan, S., Eskens, F. A. L. M., Ros, W., Diab, A., Spano, J.-P., Rizvi, N. A., Wasser, J. S., Angevin, E., Ott, P. A., Forgie, A., Yang, W., Guo, C., Chou, J., & El-Khoueiry, A. B. (2022). First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors. Journal for ImmunoTherapy of Cancer, 10(10), e005471. https://doi.org/10.1136/jitc-2022-005471

Van Nieuwenhuysen, E., O’Malley, D., O’Cearbhaill, R. E., Moore, K. N., Hamilton, E. P., Yeku, O., Bouberhan, S., Hou, J. Y., Yoo, S.-Y., Brouwer-Visser, J., Cheung, H. K., Peterman, M., Goncalves, P., Schmidt, T., Zhu, M., Lowy, I., Rowlands, T., Uldrick, T. S., Miller, E. A., & Liu, J. F. (2022). 523MO Ubamatamab (REGN4018, MUC16xCD3 bispecific antibody) monotherapy in patients with recurrent ovarian cancer (OC): Phase I dose-escalation analysis. Annals of Oncology, 33, S784. https://doi.org/10.1016/j.annonc.2022.07.651

Dimitriou, F., Namikawa, K., Reijers, I. L. M., Buchbinder, E. I., Soon, J. A., Zaremba, A., Teterycz, P., Mooradian, M. J., Armstrong, E., Nakamura, Y., Vitale, M. G., Tran, L. E., Bai, X., Allayous, C., Provent-Roy, S., Indini, A., Bhave, P., Farid, M., Kähler, K. C., … Long, G. V. (2022). Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Annals of Oncology, 33(9), 968–980. https://doi.org/10.1016/j.annonc.2022.06.004

Ingham, M., Blay, J.-Y., Baird, J., D’Silva, D., O’Keefe, K., Kong, R., Spiegel, R., Wahba, M., & Weetall, M. (2022). 1528TiP A phase II/III study evaluating the efficacy and safety of unesbulin in advanced leiomyosarcoma (SUNRISELMS). Annals of Oncology, 33, S1243–S1244. https://doi.org/10.1016/j.annonc.2022.07.1917

Kyi, C. K., Spira, A., Carbone, D. P., Johnson, M. L., Henick, B. S., Johnson, B., Borghaei, H., Mahipal, A., Hecht, J. R., Catenacci, D., Liao, C.-Y., Shergill, A., Memmott, R., Presley, C., Jaroslavsky, J., Schenk, D., Jooss, K., Ferguson, A. R., & Goldman, J. W. (2022). 736MO Personalized, off-the-shelf KRAS neoantigen-specific immunotherapy for the treatment of advanced solid tumors: Clinical benefit associated with decreases in ctDNA (SLATE-KRAS). Annals of Oncology, 33, S880. https://doi.org/10.1016/j.annonc.2022.07.862

Dimitriou, F., Hassel, J. C., Orloff, M., Hughes, I., Kapiteijn, E., Mehmi, I., Montazeri, K., Johnson, D. B., Grover, P., Gerard, C. L., Simeone, E., Gaudy Marqueste, C., Cheng, P., Long, G. V., Carvajal, R. D., & Dummer, R. (2022). 832P Treatment sequence with tebentafusp (tebe) and anti-PD1/ipilimumab (PD1+IPI) in HLA-A2*02:01 patients (pts) with metastatic uveal melanoma (mUM). Annals of Oncology, 33, S929. https://doi.org/10.1016/j.annonc.2022.07.958

Wang, P. H., Washburn, R., Maniar, R., Mu, M., Ringham, O., Kratchmarov, R., Henick, B. S., & Reiner, S. L. (2022). Cutting Edge: Promoting T Cell Factor 1+ T Cell Self-Renewal to Improve Programmed Cell Death Protein 1 Blockade. The Journal of Immunology, 209(4), 660–664. https://doi.org/10.4049/jimmunol.2200317

Sanborn, R. E., Pishvaian, M. J., Callahan, M. K., Weise, A., Sikic, B. I., Rahma, O., Cho, D. C., Rizvi, N. A., Sznol, M., Lutzky, J., Bauman, J. E., Bitting, R. L., Starodub, A., Jimeno, A., Reardon, D. A., Kaley, T., Iwamoto, F., Baehring, J. M., Subramaniam, D. S., … Keler, T. (2022). Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumors. Journal for ImmunoTherapy of Cancer, 10(8), e005147. https://doi.org/10.1136/jitc-2022-005147

Palmer, C. D., Rappaport, A. R., Davis, M. J., Hart, M. G., Scallan, C. D., Hong, S.-J., Gitlin, L., Kraemer, L. D., Kounlavouth, S., Yang, A., Smith, L., Schenk, D., Skoberne, M., Taquechel, K., Marrali, M., Jaroslavsky, J. R., Nganje, C. N., Maloney, E., Zhou, R., … Jooss, K. (2022). Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Nature Medicine, 28(8), 1619–1629. https://doi.org/10.1038/s41591-022-01937-6

Moskop, A., Pommert, L., Baggott, C., Prabhu, S., Pacenta, H. L., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J.-A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M. L., Satwani, P., Krupski, C., Keating, A. K., … Schultz, L. M. (2022). Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Advances, 6(14), 4251–4255. https://doi.org/10.1182/bloodadvances.2021006393

Lee, E. Y., Christiano, A. M., Dai, Z., & Wang, E. (2022). 065 Longitudinal analysis of T cell dynamics in alopecia areata at single-cell resolution. Journal of Investigative Dermatology, 142(8), S11. https://doi.org/10.1016/j.jid.2022.05.119